Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease
暂无分享，去创建一个
[1] B. Zinman,et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease , 2018, Circulation.
[2] B. Zinman,et al. Liraglutide and Renal Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.
[3] B. Zinman,et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. , 2017, The lancet. Diabetes & endocrinology.
[4] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[5] V. Vallon,et al. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition , 2017, Diabetologia.
[6] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[7] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[8] H. Parving,et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.